• Users Online: 94
  • Print this page
  • Email this page
CASE REPORT
Year : 2020  |  Volume : 7  |  Issue : 3  |  Page : 134-137

Successfully overcoming carboplatin hypersensitivity by continuous 48-h infusion of cisplatin plus poly (ADP-ribose) polymerase inhibitor for heavily pretreated recurrent ovarian cancer


1 Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei, Taiwan
2 Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
3 Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital; Department of Internal Medicine, School of Medicine, College of Medicine; Cancer Centre, Wanfang Hospital; Taipei Cancer Centre, Taipei Medical University, Taipei, National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan

Correspondence Address:
Dr. Gi- Ming Lai
Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei, No. 111, Section 3, Hsing-Long Road, Taipei 116
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCRP.JCRP_16_20

Rights and Permissions

The success of ovarian cancer treatment is hampered by the recurrent nature and the resistance or hypersensitivity to a platinum regimen. The addition of poly (ADP-ribose) polymerase (PARP) inhibitors can increase the sensitivity to platinum-resistant tumors, although while increasing risk of hematologic toxicity. Substituting cisplatin for carboplatin could result in satisfactory outcomes in the case of carboplatin hypersensitivity. However, there are no efficacy and safety data regarding continuous low-dose cisplatin infusion combined with an oral PARP inhibitor for ovarian cancer patients with hypersensitivity to carboplatin. Herein, we report the case of a heavily pretreated ovarian cancer patient with carboplatin hypersensitivity who safely received low-dose cisplatin (30 mg/m2 every 3 weeks) over a 48-h infusion combined with a PARP inhibitor for a total of 10 days (D− 2–D7) and successfully achieved partial response after four cycles of treatment, the efficacy of which was further enhanced by the addition of deep regional hyperthermia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed123    
    Printed4    
    Emailed0    
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal